Study of a new drug for metastatic breast cancer
Part of Cancer, Skin clinical trials.
This trial tests an experimental drug called JNJ-101684362 (HLD-0117) for people with metastatic breast cancer that has not responded to other treatments. It may help by targeting cancer cells in a new way, and the study will check if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older and have been through menopause (either naturally, surgically, or with medication to stop ovaries).
- You have metastatic or locally advanced breast cancer that has gotten worse on your latest treatment.
- You have already tried at least one hormone therapy (like tamoxifen or an aromatase inhibitor) and at least one CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib).
- You have a tumor that can be measured or seen on scans, and you are willing to give biopsy samples (unless not safe or possible).
- Your cancer has enough estrogen receptors (ER-positive) and is HER2-negative.
- You are in good enough health to manage daily activities (ECOG 0-1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests a new combination of two study drugs (JSKN016 and D-0502) for people with a common type of advanced breast cancer (HR-positive, HER2-negative) that has grown after standard hormonal and CDK4/6 inhibitor treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
This trial tests a new drug, JNJ-87704916, given alone or with other treatments for people with advanced solid tumors that have stopped responding to standard therapies. It may be an option if you have a tumor that can be injected and are in good overall health.
This trial tests an experimental drug (JNJ-101556143) for men with metastatic prostate cancer that has stopped responding to hormone therapy. The goal is to see if this drug can slow down or stop the cancer from growing.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.